Akamis Bio
PrivateLast Round
Series A
Dec 17, 2024
Total Funding Raised
$226.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Akamis Bio is a biotechnology company developing systemically administered oncolytic immunotherapies to treat solid tumors through its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Akamis Bio Comparables
Compare Akamis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Virogin Biotech | 85% | |
| Theolytics | 83% | |
| Lokon Pharma | 81% |
Akamis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 17, 2024 | ||||
| Convertible Debt | Jan 5, 2023 | ||||
| Corporate Funding | Dec 20, 2016 | ||||
| Series C | May 19, 2015 | ||||
| Grant | Nov 6, 2012 | ||||
Series B | Jul 19, 2012 |
Key People
Founding team and executive leadership
Akamis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series B, Series C |
| Invesco Ltd. | Series B, Series A, VC Round, Series C |
| Westlake Village BioPartners | Convertible Debt |
| IP Group | Convertible Debt |
| Lundbeckfonden BioCapital | Series B, Series C |
| ARCH Venture Partners | Convertible Debt |
| Parker Institute for Cancer Immunotherapy | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 79% MoM.
- Oct 14, 2025
NG-350A receives designation for advanced rectal cancer treatment.
Akamis Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Akamis Bio's valuation, stock price, and market status.
Is Akamis Bio a public or private company?
Akamis Bio is a private company.
What is the current stock price of Akamis Bio?
Akamis Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Akamis Bio worth (valuation)?
Valuation information for Akamis Bio is not publicly available.
Can I buy Akamis Bio stock?
Akamis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Akamis Bio's last funding round?
Akamis Bio's most recent funding round was Series A on December 17, 2024.
Who are the main investors in Akamis Bio?
Key investors in Akamis Bio include Westlake Village Biopartners, Parker Institute for Cancer Immunotherapy, ARCH Venture Partners, Imperial Innovations, Sedgwick Yard.
Will Akamis Bio IPO soon?
No public IPO plans have been announced for Akamis Bio.
How can I track Akamis Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Akamis Bio's secondary market activity and sign up for updates.